ArticleDrugs - real world outcomes2024

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.

Jessica A Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.